Gender

Visit number vs C-Reactive Protein, Cardiac
N Mean StdDev Median Min Max Unknown Total
Baseline 49 4.9 ± 3.6 4.2 0.2 18.3 - 49
9-Month Followup 43 4.6 ± 4.7 3.3 0.3 20.6 - 43
18-Month Followup 40 3.5 ± 3.5 2.4 0.5 19.2 - 40
Randomized treatment arm vs C-Reactive Protein, Cardiac
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 49 4.9 ± 3.6 4.2 0.2 18.3 - 49
Laparoscopic Gastric Banding (LGB) 28 5.3 ± 3.8 4.7 0.2 18.3 - 28
Continuous Positive Airway Pressure (CPAP) 21 4.3 ± 3.3 3.8 0.7 12.2 - 21
Randomized treatment arm vs C-Reactive Protein, Cardiac
9-Month Followup
N Mean StdDev Median Min Max Unknown Total
Total 43 4.6 ± 4.7 3.3 0.3 20.6 - 43
Laparoscopic Gastric Banding (LGB) 25 4.9 ± 4.9 2.6 0.7 18.2 - 25
Continuous Positive Airway Pressure (CPAP) 18 4.3 ± 4.6 3.4 0.3 20.6 - 18
Randomized treatment arm vs C-Reactive Protein, Cardiac
18-Month Followup
N Mean StdDev Median Min Max Unknown Total
Total 40 3.5 ± 3.5 2.4 0.5 19.2 - 40
Laparoscopic Gastric Banding (LGB) 24 3.3 ± 3.8 2.4 0.5 19.2 - 24
Continuous Positive Airway Pressure (CPAP) 16 3.8 ± 3.2 3.1 0.5 10.5 - 16
Age of the participant vs C-Reactive Protein, Cardiac
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 49 4.9 ± 3.6 4.2 0.2 18.3 - 49
27.0 to 45.0 years 13 4.6 ± 3.8 3.2 0.9 12.2 - 13
46.0 to 50.0 years 12 4.4 ± 3.1 4.0 0.7 12.0 - 12
51.0 to 56.0 years 12 5.1 ± 3.0 4.9 1.0 12.3 - 12
57.0 to 65.0 years 12 5.6 ± 4.7 4.3 0.2 18.3 - 12
Age of the participant vs C-Reactive Protein, Cardiac
9-Month Followup
N Mean StdDev Median Min Max Unknown Total
Total 43 4.6 ± 4.7 3.3 0.3 20.6 - 43
28.0 to 47.0 years 11 3.0 ± 2.0 2.9 0.3 6.1 - 11
47.0 to 52.0 years 11 5.1 ± 6.3 2.6 0.4 18.2 - 11
52.0 to 58.0 years 11 6.3 ± 5.4 4.1 2.3 20.6 - 11
58.0 to 65.0 years 10 4.1 ± 3.9 2.8 1.1 13.6 - 10
Age of the participant vs C-Reactive Protein, Cardiac
18-Month Followup
N Mean StdDev Median Min Max Unknown Total
Total 40 3.5 ± 3.5 2.4 0.5 19.2 - 40
29.0 to 46.0 years 10 3.3 ± 2.7 2.7 1.2 10.5 - 10
47.0 to 52.0 years 10 2.9 ± 2.6 2.0 0.5 6.4 - 10
53.0 to 58.0 years 10 4.1 ± 2.7 3.2 1.6 10.2 - 10
58.0 to 65.0 years 10 3.6 ± 5.7 1.6 0.5 19.2 - 10
Gender of the participant vs C-Reactive Protein, Cardiac
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 49 4.9 ± 3.6 4.2 0.2 18.3 - 49
Male 28 3.7 ± 2.9 3.3 0.2 12.2 - 28
Female 21 6.5 ± 4.0 6.3 1.5 18.3 - 21
Gender of the participant vs C-Reactive Protein, Cardiac
9-Month Followup
N Mean StdDev Median Min Max Unknown Total
Total 43 4.6 ± 4.7 3.3 0.3 20.6 - 43
Male 25 3.7 ± 3.8 2.6 0.3 18.2 - 25
Female 18 5.9 ± 5.7 4.1 0.7 20.6 - 18
Gender of the participant vs C-Reactive Protein, Cardiac
18-Month Followup
N Mean StdDev Median Min Max Unknown Total
Total 40 3.5 ± 3.5 2.4 0.5 19.2 - 40
Male 25 3.0 ± 2.3 1.9 0.5 10.5 - 25
Female 15 4.3 ± 4.9 2.6 0.5 19.2 - 15
Race of the participant vs C-Reactive Protein, Cardiac
Baseline
N Mean StdDev Median Min Max Unknown Total
Total 46 5.0 ± 3.7 4.4 0.2 18.3 - 46
white 35 5.4 ± 3.7 4.7 1.0 18.3 - 35
american indian or alaska native - - - - - - - -
black or african american 9 4.4 ± 3.7 3.5 0.2 12.0 - 9
asian 2 1.0 ± 0.07 1.0 0.9 1.0 - 2
native hawaiian or other pacific islander - - - - - - - -
other - - - - - - - -
multiple - - - - - - - -
Race of the participant vs C-Reactive Protein, Cardiac
9-Month Followup
N Mean StdDev Median Min Max Unknown Total
Total 40 4.8 ± 4.9 3.3 0.3 20.6 - 40
white 31 4.4 ± 3.9 3.4 0.7 18.2 - 31
american indian or alaska native - - - - - - - -
black or african american 8 6.7 ± 7.7 3.7 0.4 20.6 - 8
asian 1 0.3 - 0.3 0.3 0.3 - 1
native hawaiian or other pacific islander - - - - - - - -
other - - - - - - - -
multiple - - - - - - - -
Race of the participant vs C-Reactive Protein, Cardiac
18-Month Followup
N Mean StdDev Median Min Max Unknown Total
Total 37 3.5 ± 3.6 2.4 0.5 19.2 - 37
white 29 3.0 ± 2.4 2.4 0.5 10.5 - 29
american indian or alaska native - - - - - - - -
black or african american 7 5.9 ± 6.6 6.3 0.5 19.2 - 7
asian 1 1.8 - 1.8 1.8 1.8 - 1
native hawaiian or other pacific islander - - - - - - - -
other - - - - - - - -
multiple - - - - - - - -